Led · Series A · Jan 2026

Corsera Health is pursuing a vision of eliminating cardiovascular disease by pairing AI-enabled risk prediction with long-acting RNA interference therapeutics. Its lead program targets the two main drivers of atherosclerotic cardiovascular disease—elevated LDL-C and high blood pressure—using subcutaneously administered siRNA molecules that silence PCSK9 (COR-1004) and AGT (COR-2003). COR-1004 has begun dosing in a Phase 1 trial focused on safety, PCSK9 knockdown, and LDL-C reduction, with initial proof-of-concept data expected in 2026; the AGT program is slated to enter Phase 1 in mid-2026. Both agents are designed for once-yearly administration to enable population-scale prevention. Complementing the therapeutics, the company’s proprietary AI platform, Klotho, models lifetime ASCVD risk and quantifies the benefit of lowering LDL-C and blood pressure. The integrated approach aims to shift care from late-stage intervention to true prevention and extend healthspan. Corsera’s $80 million Series A financing provides the capital to advance these clinical programs and further develop the Klotho platform.

Participated · Series A · Feb 2024

Areteia Therapeutics is a clinical-stage biotech focused on developing oral inflammation and immunology therapies, initially targeting severe eosinophilic asthma with dexpramipexole. Dexpramipexole is an oral small-molecule eosinophil maturation inhibitor that lowered blood eosinophil counts in Phase II testing and was well tolerated. The company has initiated late-stage development, running three Phase III trials in partnership with Population Health Partners’ development unit, Validae Health. Areteia was created by Population Health Partners and Knopp Biosciences and is backed by a syndicate led by Bain Capital Life Sciences alongside other life-sciences and strategic investors. Financially, Areteia has secured up to $425 million in Series A commitments after an additional $75 million expansion, strengthening its capitalization to support late-stage development and commercial supply. Planned uses of proceeds include expanding Phase III development into Japan and additional global markets, expanding manufacturing, and life-cycle management such as a once-daily formulation. Areteia Therapeutics was launched to develop dexpramipexole, a first-in-class oral eosinophil maturation inhibitor and the company’s lead drug candidate. Dexpramipexole is described as an oral small molecule that inhibits maturation and release of eosinophils and is in Phase 3 development for eosinophilic asthma. In a Phase 2 study, dexpramipexole produced a significant, dose-dependent reduction in blood absolute eosinophil counts and was well tolerated with no serious adverse events or discontinuations. Areteia plans to conduct late-stage development including Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. The company was created by Population Health Partners and Knopp Biosciences and will partner with Population Health Partners’ Validae Health unit on the development program. Jorge Bartolome has been appointed CEO and a board including representatives from Knopp, Bain Capital Life Sciences, Population Health Partners, and Arch Ventures will oversee the company.

Participated · Equity · Oct 2021

Saama Technologies offers the Life Science Analytics Cloud (LSAC), an AI-driven clinical data platform. LSAC is used by over 50 pharma and biotech companies on more than 1,500 studies and provides a unified approach to clinical trial data management and analytics. Its pre-trained, AI-embedded smart applications learn complex patterns in clinical data and deliver predictive insights to accelerate the clinical research process across multiple domains and therapeutic areas. The company intends to use the investment to accelerate strategic initiatives, expand go-to-market capabilities, and further invest in AI research and development. Saama is led by founder and CEO Suresh Katta and is based in Campbell, California. Saama Technologies, based in Campbell, Calif., operates the Life Science Analytics Cloud (LSAC), an AI-powered platform that ingests, integrates, curates, and harmonizes clinical trial operational and patient data from proprietary and external sources. LSAC uses a novel deep learning approach to deliver actionable, regulatory-ready insights and, according to the company, significantly compresses clinical program timelines from clinical plan development to submission judgment for a New Drug Application (NDA). Saama intends to use the proceeds of the financing to expand LSAC and to strengthen its ecosystem of pharma and biotech partners, academia, data providers, and CROs. The company plans to build a suite of collective innovations leveraging the LSAC platform to accelerate clinical trials and reduce costs. The new financing brings Saama's total capital raised since 2015 to $75 million. Suresh Katta is Founder and CEO of Saama. Saama combines its Fluid Analytics Engine, packaged Ready Analytics solutions, services and strategic partnerships to help customers quickly uncover and operationalize strategic data assets. The company focuses on delivering industry-specific analytics that drive concept-to-action-to-value within a short performance period. Saama serves Global 2000 clients and lists customers including Actelion, Brocade, Broadcom, Cisco, CSAA Insurance, Delta Dental, Dignity Health, PayPal, Salesforce.com and Unilever. Headquartered in Silicon Valley, the company emphasizes a solutions-based approach that pairs software and services to create immediate customer value. With the new funding, Saama plans to expand its Ready Analytics solutions and increase its Big Data leadership to meet market demand. The announcement frames the investment as the company’s first institutional capital and a minority financing used to accelerate deployment of its analytics offerings.

Led · Series F · Jun 2021

Fractyl Health is developing Revita DMR, an outpatient endoscopic procedure that resurfaces the duodenal mucosa to treat insulin resistance and metabolic disease. Revita DMR has been studied in close to 300 patients and has received FDA Breakthrough Device Designation for T2D patients treated with insulin, as well as a CE mark in the EU. In the U.S. the device is not yet authorized for marketing and is being evaluated under an FDA-approved Investigational Device Exemption study. The company says its discoveries could address other metabolic diseases such as NAFLD/NASH and aim to reduce the global healthcare and economic burden of metabolic disease. Proceeds from the recent financing will support initiation of multiple late-stage clinical studies and accelerate ongoing REVITA-T2Di work to establish Revita DMR as a cornerstone therapy and reduce insulin dependence. Fractyl is based in Lexington, Mass., and recently renamed itself Fractyl Health to reflect its broader mission. Fractyl Laboratories is developing Revita DMR, a same-day, outpatient endoscopic procedure that uses heat to resurface the duodenal mucosa to reset metabolic pathways and address insulin resistance. Clinical data from close to 300 patients at more than 20 centers across three continents have shown durable improvements in type 2 diabetes and fatty liver disease and a favorable safety profile with no long-term adverse events reported. The Revita DMR System received a CE mark in April 2016 and the CE label was expanded in March 2020 to include insulin withdrawal, improvements in NAFLD/NASH in patients with T2D, and improved insulin sensitivity in PCOS. In the United States, Revita is approved for investigational use only by the FDA. Fractyl announced a first close of $55 million in a Series E financing; proceeds will support the Revita T2Di pivotal clinical trial examining glycemic control and insulin requirements, with a primary endpoint of percentage of patients achieving HbA1c ≤7% without insulin at 24 weeks versus sham. The company plans to initiate its pivotal U.S. trial later this year and use the financing to advance its regulatory and development activities for metabolic disease indications. Fractyl Labs develops Revita Duodenal Mucosal Resurfacing (DMR), an outpatient procedure intended to rejuvenate the duodenum and improve insulin sensitivity in people with type 2 diabetes. The company reports that a one-time Revita DMR treatment yields insulin-sensitizing effects and durable improvements in hepatic and glycemic indices over a year without intensive lifestyle changes. Fractyl plans to use the new funding to continue development of its Revita DMR technology and to support an ongoing Revita-2 multi-center clinical study, which began enrolling patients in Europe in May. Last year the Revita DMR System received a CE mark in the European Union. The company aims to submit an investigational device application with the U.S. Food and Drug Administration to enable investigational use in the United States. Fractyl recently raised $44 million in a Series D financing from multiple venture firms to advance these efforts. Fractyl Laboratories develops the Revita Duodenal Mucosal Resurfacing (DMR) system, a same-day, minimally invasive procedure intended to improve metabolic health in patients with type 2 diabetes. The approach is based on bariatric surgery procedures and aims to produce meaningful improvements in blood sugar and potentially reduce the need for additional medications. The company reported results from a 39-patient, single-site proof-of-concept study showing significant, beneficial changes in blood sugar and has treated 28 patients in its first international multicenter clinical trial. A multicenter Revita-1 trial is currently underway in Europe and South America, and Fractyl plans to begin randomized studies next year. Fractyl recently completed a $57M Series C extension to support and accelerate its clinical development and path to market. The company is headquartered in Waltham, MA, and its Revita system remains for investigational use only while trials continue. Fractyl Labs is developing Revita DMR, a non-invasive duodenal mucosal resurfacing procedure intended to alter the inner surface of the duodenum to change how the body absorbs sugar. The company says the procedure can potentially delay the need for insulin injections in patients with type 2 diabetes. Fractyl reported positive clinical data from a single-site study in Santiago, Chile showing a greater than two percentage-point drop in hemoglobin A1C at three months in 19 of 30 patients, with those 19 maintaining the same blood sugar level at six months. The effectiveness appeared dose-dependent: shorter treated segments produced smaller benefits. Fractyl is preparing to launch a multinational study by the end of 2014 and expects to start U.S. clinical development in 2016. The company is based in Waltham, Massachusetts, and is led by CEO and founder Dr. Harith Rajagopalan.

Participated · Series C · Apr 2021

Adagio Therapeutics develops monoclonal antibodies designed to broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. Its lead clinical candidate, ADG20, targets the spike protein and displays potent neutralizing activity against the original SARS-CoV-2 strain and known variants of concern. ADG20 is formulated at high concentrations to enable intramuscular administration, engineered for a long half-life, and may act via direct neutralization and Fc-mediated elimination of infected cells. The company has initiated a Phase 1 study in healthy volunteers and a pivotal Phase 1/2/3 STAMP trial in high-risk individuals with mild or moderate COVID-19, and plans a third trial in Q2 2021 to evaluate prevention of symptomatic COVID-19. Adagio has secured third-party manufacturing capacity to support clinical trials and potential initial commercial launch. The company intends to use recently raised funds to continue advancement of ADG20 for treatment and prevention of COVID-19 and potential future coronaviruses. Adagio Therapeutics is developing best-in-class, broadly neutralizing monoclonal antibodies targeting a conserved epitope on the spike protein of beta‑coronaviruses that use ACE2. Its lead candidate, ADG20, was selected after rapid candidate optimization and is designed for potency, extended half-life, manufacturability, tolerability, and affordability. The company established a manufacturing agreement and completed production runs for ADG20 intended for clinical trials. Adagio has received positive feedback from the FDA and plans a first‑in‑human study of ADG20 in early 2021 to support both treatment and prevention of COVID‑19. The proceeds of the recent financing will fund rapid advancement of ADG20 into clinical development. The company launched in late June and is headquartered in Waltham, Mass. Adagio is developing engineered, broadly neutralizing monoclonal antibodies that bind a highly conserved epitope on the coronavirus spike protein to neutralize SARS-CoV-2, SARS-CoV-1 and additional circulating bat coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets intended to reduce the risk of viral escape, and candidates have been optimized for potency and extended duration of effect. The company was spun out of Adimab, LLC and leverages Adimab's antibody-discovery capabilities. Adagio launched with a $50 million Series A financing intended to advance lead candidates through IND-enabling studies and into early clinical development. The lead program is expected to enter the clinic by the end of 2020, and the company envisions prophylactic use with infrequent dosing (twice a year) and potential greater than 90% protection. A senior team of infectious disease drug developers and biotechnology executives will lead development, manufacturing, and clinical efforts.